**A review of monofilament fibre technology in the management of a variety of dermatological conditions**

Clare Morris, Senior Clinical Services Manager, L&R

**Aims**
To review the evidence supporting the use of monofilament fibre debridement technology* in dermatological conditions.

**Methods**
Monofilament fibre debridement technology has been successfully used for 7 years in the debridement and management of chronic wounds¹ and hyperkeratosis². In recent years clinicians have been utilising the technology in specific dermatological skin conditions.

**Results/Discussion**
Monofilament fibre debridement technology has been shown in case studies and case series to be a useful emerging treatment, especially when self-care is a priority, in the management of dermatological conditions, for example;

- **Varicose eczema³,⁴** (Figures 1, 2 and 3)

- **Epidermolysis bullosa⁵**

- **Chronic wounds in dermatological patients⁶**

- **Dry, scaly and flaky skin conditions⁷,⁸,⁹** (Figures 4 and 5)

- **Hyperkeratosis associated with venous disease²,¹⁰**

- **Secondary skin changes associated with chronic oedema and lymphoedema¹¹,¹²,¹³,¹⁴**

- **Actinic keratosis¹⁵** (Figures 6 and 7)
Prior to photodynamic therapy \(^{16}\) (Figures 8 and 9)

Acne vulgaris\(^{17/18}\)

The 18 million special monofilament fibres which have angled tips to reach uneven areas of the skin or wound bed, are able to remove unwanted tissue, materials and skin, allowing other concurrent treatment to reach their target area without the barriers imposed by for e.g. devitilised tissue, dry, scaly and flaky skin and other debris and materials.

This technology has received positive NICE guidance\(^{19}\) for use in acute and chronic wounds.

Monofilament fibre debridement technology is very soft, comfortable and gentle on patients. It is safe and easy to use and can also be used by patients for self-care.

**Conclusion**

A review of the available evidence clearly supports the continued research and interest in monofilament fibre debridement technology related to dermatological conditions.

**References**

7. Unpublished data on file
8. Unpublished data on file

*Debrisoft®/Debrisoft® Lolly – L&R*

EWMA Conference, Krakow, Poland, 9-11 May 2018.